Abstract
Susac syndrome (SuS) presents with encephalopathy, visual disturbances, and hearing loss from immune-mediated microvascular occlusion. While acute SuS is well-described, long-term cognitive outcomes with current treatments are underknown. We assessed ten SuS patients treated in accordance with evidence-based guidelines using immunotherapies targeting humoral and cell-mediated pathways. Patients were followed for a median 3.6 years. Initially, cognition inversely correlated with corpus callosum lesions on MRI. All reported cognitive improvement; 5/10 patients had residual deficits in visual attention and executive function. Early, aggressive treatment was associated with good outcomes; extensive early corpus callosum lesions may identify patients at-risk of persistent cognitive deficits.
Original language | English |
---|---|
Article number | 578396 |
Pages (from-to) | 578396 |
Journal | Journal of Neuroimmunology |
Volume | 393 |
DOIs | |
State | Published - 15 Aug 2024 |
Bibliographical note
Copyright © 2024 Elsevier B.V. All rights reserved.Keywords
- Cognition
- Corpus callosum
- Immunotherapy
- Susac syndrome